Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
56.72
+2.19 (4.02%)
Aug 13, 2025, 4:00 PM - Market closed
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Protagonist Therapeutics stock ranges from a low of $57 to a high of $80. The average analyst price target of $70.13 forecasts a 23.64% increase in the stock price over the next year.
Price Target: $70.13 (+23.64%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $67 → $69 | Buy | Maintains | $67 → $69 | +21.65% | Aug 7, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +26.94% | Jun 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +41.04% | Jun 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +41.04% | May 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +41.04% | Apr 10, 2025 |
Financial Forecast
Revenue This Year
82.91M
from 434.43M
Decreased by -80.91%
Revenue Next Year
126.93M
from 82.91M
Increased by 53.09%
EPS This Year
-1.98
from 4.23
EPS Next Year
-1.79
from -1.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 266.1M | 302.4M | 711.9M | ||
| Avg | 82.9M | 126.9M | 210.4M | ||
| Low | 27.7M | 19.6M | 46.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -38.8% | 264.7% | 460.9% | ||
| Avg | -80.9% | 53.1% | 65.8% | ||
| Low | -93.6% | -76.4% | -63.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.23 | -0.58 | -0.17 | ||
| Avg | -1.98 | -1.79 | -1.23 | ||
| Low | -2.47 | -3.64 | -2.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.